Stoke Therapeutics adds Alexander Cumbo to board after Kaye resignation

Stoke Therapeutics disclosed in an 8-K that Edward M. Kaye, M.D. notified the board on September 22, 2026 of his intent to resign as a Class III director and as a member of the Research and Development Committee, effective September 23, 2026¹. The company said Dr. Kaye's resignation was not the result of any disagreement with the Company¹.

The board acted on September 23, 2026 to fill the vacancy, and appointed Alexander (Bo) Cumbo to serve as a Class III director effective that same day, based on a recommendation from the board's Nominating and Corporate Governance Committee¹. Stoke said Cumbo will hold office until the 2028 Annual Meeting of stockholders, the next meeting at which Class III directors are elected¹.

The filing states that there was no arrangement or understanding involving Cumbo's selection as director, and he has no direct or indirect material interest in any transaction with Stoke requiring disclosure under Item 404(a) of Regulation S-K¹. The board also determined that Cumbo qualifies as an independent director under SEC rules and Nasdaq listing standards¹. Stoke noted that Cumbo signed the same indemnity agreement form the company uses for its directors and executive officers, originally filed as Exhibit 10.1 to Stoke's 2019 S-1 registration statement¹.

On compensation, the company said Cumbo will receive an annual cash retainer of $45,000 for board service¹. Additionally, he was granted a stock option to purchase 39,674 shares under Stoke's 2019 Equity Incentive Plan, with a target grant date fair value of approximately $724,000 under ASC 718, vesting in twelve equal quarterly installments¹. The filing was signed by Chief Financial Officer Thomas E. Leggett on September 25, 2026.